Lipoprotein Heterogeneity and its Effect on Apolipoprotein Assays

References

• Mahley R W, Innerarity T L, Rail S C, Weisgraber K H. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984; 25: 1277–1291
   PubMed Web of Science ®Google Scholar
• Schneider W J, Beisiegel U. Tissue-lipoprotein interactins: lipoproteins receptors. Human Plasma Lipoproteins, J C Fruchart, J Shepherd. Walter de Gruyter, Berlin 1989
   Google Scholar
• Alaupovic P. The physicochemical and immunological heterogeneity of human plasma high-density lipoproteins. Clinical and Metabolic Aspects of High-Density Lipoproteins, N E Miller, G F Miller. Elsevier Science Publishers, Amsterdam 1984
   Google Scholar
• Alaupovic P. The concepts, classification systems and nomenclature of human plasma lipoproteins. Lipoproteins: Basic Principles and Concepts, L A Lewis, J J Opplt. CRC Press, Inc Boca Raton, , Florida 1980
   Google Scholar
• Fruchart J C, Fievet C, Puchois P. Apo-lipoproleins. Methods of Enzymatic Analysis, H U Bergmeyer. VCH, Weinheim 1985
   Google Scholar
• Fruchart J C. Polycloncal, oligoclonal and monoclonal antibody mapping of lipoprotein particles. Atherosclerosis VII, N H Fidge, P J Nestel. Elsevier Science Pub-Ushers B.V. 1986
   Google Scholar
• Vu-Dac N, Mezdour H, Parra H J, Luc G, Luyeye I, Fruchart J C. A selective bi-site immunoenzymometric procedure for human Lp(a) lipoprotein quantification using monoclonal antibodies against apo (a) and apo B. J Lipid Res. 1989, in press
   PubMed Web of Science ®Google Scholar
• Koren E, Puchois P, Alaupovic P, Fesmire J, Kandoussi A, Fruchart J C. Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay. Clin Chem 1987; 33: 38–47
   PubMed Web of Science ®Google Scholar
• Parra H J, Mezdour H, Ghalim N, Bard J M, Fruchart J C. Differential electroimmunoassay on ready-to-use plates for human LpA-I lipoprotein particles. Clin Chem 1989, in press
   PubMed Web of Science ®Google Scholar
• Maciejko J J, Homes D R, Kottke B A, Zinsmeister A R, Dinh D M, Mao S JT. Apolipoprotein A-I as a marker of angiographically assessed coronary artery disease. N Engl J Med 1983; 309: 385–389
   PubMed Web of Science ®Google Scholar
• Brunzell J D, Sniderman A D, Albers J J, Kwiterovich P D, Jr. Apolipoprotein B and A-I and coronary artery disease in humans. Arterosclerosis 1984; 4: 79–83
   PubMedGoogle Scholar
• Barbaras R, Grimaldi P, Négrel R, Ailhaud G. Binding of lipoproteins and regulation of cholesterol synthesis in cultured mouse adipose cells. Biochim Biophys Acta 1985; 845: 492–501
   PubMed Web of Science ®Google Scholar
• Barbaras R, Puchois P, Fruchart J C, Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LpA-I particles but not by LpA-I:A-II particles. Biochem Biophys Res Commun 1987; 142: 63–69
   PubMed Web of Science ®Google Scholar
• Puchois P, Steinmetz A, Ghalim N, Barbaras R, Barkia A, Ailhaud G, Fruchart J C. Characterization of lipoproteins containing apo A-I but not apo A-II from human interstitial fluid. The American Heart Association, 61 th Scientific Sessions. November 14–17, 1988
   Google Scholar
• Puchois P, Kandoussi A, Fievet P, Fourrier J L, Bertrand M, Koren E, Fruchart J C. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987; 68: 35–40
   PubMed Web of Science ®Google Scholar
• Luc G, Bard J M, Lussier-Cacan S, Parra H J, Fruchart J C, Davignon J. High density lipoprotein particles in octogenarians. Metabolism 1989, in press
   Web of Science ®Google Scholar
• Ghalim N, Puchois P, Zylberberg G, Fievet P, Demarquilly C, Fruchart J C. Effect of alcohol intake on human apolipoproteins A-I containing lipoproteins subtractions. Arch Int Med 1989, in press
   Google Scholar
• Bard J M, Parra H J, Douste-Blazy P, Fruchart J C. Effect of pravastatin and HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism 1989, in press
   Web of Science ®Google Scholar
• Bard J M, Parra H J, Douste-Blazy P, Fruchart J C. Comparative effects of pravastatin, a new HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on plasma lipids and apolipoproteins in primary hypercholesterolemia. Europ J Clin Pharm 1989, in press
   PubMed Web of Science ®Google Scholar
• Alaupovic P. The role of apolipoproteins in lipid transport processes. Ric Clin Lab 1982; 12: 3–21
   PubMedGoogle Scholar
• Bard J M, Agnani G, Candelier L, Clavey V, Fruchart J C. Influence of apolipoprotein composition on the lipoprotein binding properties for the B:E receptor of HeLa cells. International Atherosclerosis Congress, Vienna, April, 20–221989
   Google Scholar
• Fruchart J C, Kandoussi A, Parsy D, Koren E, Puchois P. Measurement of lipoprotein particles defined by their apolipoprotein composition using immunosorbent assay. Annual Meeting on Clinical Chemistry, Mannheim, September 25–28, 1985. J Clin Chem Clin Biochem (abslr) 1985; 23: 619
   Google Scholar
• Bard J M. Effect of bile acid sequestrants, fibrates, and HMG CoA reductase inhibitors on lipoproteins particles. 36th Colloguium on Protides of the Biological Fluids, London, April, 3–51989
   Google Scholar
• Lussier-Cacan S, Bard J M, Boulel L, Nestruck A L, Grothe A M, Fruchart J C, Davignon J. Lipoprotein composition changes induced by fenofibrale in dysbetalipoproteinemia type III. Atherosclerosis 1989; 78: 167–182
   PubMed Web of Science ®Google Scholar